SAFETY AND PROOF OF PRINCIPLE STUDY OF ATX-MS-1467 IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS: OPEN LABEL UPWARD TITRATION OVER FIVE DOSE LEVELS AND USING TWO ROUTES OF ADMINISTRATION (INTRADERMAL AND SUBCUTANEOUS).
Latest Information Update: 10 Nov 2021
At a glance
- Drugs WP 1303 Worg Pharmaceuticals (Primary) ; WP 1303 Worg Pharmaceuticals (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Sponsors Apitope Technology
- 12 Feb 2018 Results published in the Neurology
- 03 May 2014 Results presented at the 66th Annual Meeting of the American Academy of Neurology.
- 03 Sep 2013 Results have been reported in an Apitope media release. New Gd and total Gd enhancing lesions, on MRI, were decreased with intradermal ATX-MS-1467 but not with subcutaneous ATX-MS-1467.